Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mach7 Technologies ( (AU:M7T) ) has provided an update.
Mach7 Technologies has completed its on-market share buy-back program, which ran from late January 2025 to early March 2026 and was originally authorised for purchases of up to $5 million in fully paid ordinary shares. The company ultimately repurchased 6,273,000 shares for a total consideration of about $2.24 million at an average price of $0.3501, reducing its share count and potentially enhancing earnings per share and capital management flexibility for existing investors.
The most recent analyst rating on (AU:M7T) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies is an ASX-listed provider of medical imaging software, specialising in enterprise imaging solutions for healthcare organisations worldwide. Its Mach7 Enterprise Imaging Solution combines a vendor neutral archive, the eUnity enterprise diagnostic viewer, and workflow applications, serving customers from large integrated delivery networks and national health systems to independent provider groups and private radiology practices.
Average Trading Volume: 292,660
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$76.38M
For an in-depth examination of M7T stock, go to TipRanks’ Overview page.